Jasim Dhifaf A, Boutin Herve, Fairclough Michael, Ménard-Moyon Cécilia, Prenant Christian, Bianco Alberto, Kostarelos Kostas
Thickness of functionalized graphene oxide sheets plays critical role in tissue accumulation and urinary excretion: A pilot PET/CT study Article de journal
Dans: Applied Materials Today, vol. 4, p. 24–30, 2016, ISSN: 2352-9407.
Résumé | Liens | BibTeX | Étiquettes: carbon, I2CT, imaging, Nanomedicine, Pharmacokinetics, Pharmacology, Team-Bianco
@article{jasim_thickness_2016,
title = {Thickness of functionalized graphene oxide sheets plays critical role in tissue accumulation and urinary excretion: A pilot PET/CT study},
author = {Dhifaf A Jasim and Herve Boutin and Michael Fairclough and Cécilia Ménard-Moyon and Christian Prenant and Alberto Bianco and Kostas Kostarelos},
url = {http://www.sciencedirect.com/science/article/pii/S2352940716300099},
doi = {10.1016/j.apmt.2016.04.003},
issn = {2352-9407},
year = {2016},
date = {2016-09-01},
urldate = {2020-04-01},
journal = {Applied Materials Today},
volume = {4},
pages = {24--30},
abstract = {We have recently reported that administration of thin graphene oxide (GO) sheets in the systemic circulation of rodents leads to rapid urinary excretion for the majority of injected dose and accumulation by the reticuloendothelial system organs for the remaining dose. In this study, graphene oxide was functionalized with a chelating moiety (DOTA, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)) and labeled with [64Cu] for positron emission computed tomography (PET/CT) imaging. The thin functionalized graphene oxide material (f-GO-thin) consisted of a few layers (∼5nm) in thickness. Aging of the f-GO-thin material led to re-stacking of the flakes that resulted in materials of increased thickness (f-GO-thick) without altering their lateral dimension. These two types of f-GOs were comparatively studied pharmacologically to reveal the previously unexplored in vivo role of graphene oxide sheet thickness. Our results showed that a significantly larger fraction of the thicker GO sheets (47.5% of injected dose) remained within the body of living animals 24h after intravenous administration, residing mainly in the spleen and liver. The thinner GO sheets were predominantly (76.9% of injected dose) excreted through the glomerular filter into the urine. This pilot study provides an initial correlation between graphene-based material structure and pharmacological profile that is imperative towards understanding of how 2D structures behave in vivo to give information on potential biomedical applications.},
keywords = {carbon, I2CT, imaging, Nanomedicine, Pharmacokinetics, Pharmacology, Team-Bianco},
pubstate = {published},
tppubtype = {article}
}
Lacerda Lara, Bianco Alberto, Prato Maurizio, Kostarelos Kostas
Carbon nanotubes as nanomedicines: from toxicology to pharmacology Article de journal
Dans: Advanced Drug Delivery Reviews, vol. 58, no. 14, p. 1460–1470, 2006, ISSN: 0169-409X.
Résumé | Liens | BibTeX | Étiquettes: Animals, carbon, Humans, I2CT, Nanomedicine, Nanotubes, Pharmacokinetics, Pharmacology, Team-Bianco
@article{lacerda_carbon_2006,
title = {Carbon nanotubes as nanomedicines: from toxicology to pharmacology},
author = {Lara Lacerda and Alberto Bianco and Maurizio Prato and Kostas Kostarelos},
doi = {10.1016/j.addr.2006.09.015},
issn = {0169-409X},
year = {2006},
date = {2006-12-01},
journal = {Advanced Drug Delivery Reviews},
volume = {58},
number = {14},
pages = {1460--1470},
abstract = {Various biomedical applications of carbon nanotubes have been proposed in the last few years leading to the emergence of a new field in diagnostics and therapeutics. Most of these applications will involve the administration or implantation of carbon nanotubes and their matrices into patients. The toxicological and pharmacological profile of such carbon nanotube systems developed as nanomedicines will have to be determined prior to any clinical studies undertaken. This review brings together all the toxicological and pharmacological in vivo studies that have been carried out using carbon nanotubes, to offer the first summary of the state-of-the-art in the pharmaceutical development of carbon nanotubes on the road to becoming viable and effective nanomedicines.},
keywords = {Animals, carbon, Humans, I2CT, Nanomedicine, Nanotubes, Pharmacokinetics, Pharmacology, Team-Bianco},
pubstate = {published},
tppubtype = {article}
}